Absorption, Distribution, Metabolism and Excretion (ADME) study with single oral administration of [14C] NKTR-118
Study identifier:D3820C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Open-Label, Single-Centre Study to Assess Absorption, Distribution, Metabolism and Excretion (ADME) after [14C]-labelled Oral Administration of NKTR-118 to Healthy Male Volunteers
Medical condition
Healthy Volunteers
Phase
Phase 1
Healthy volunteers
Yes
Study drug
[14C] NKTR-118
Sex
Male
Actual Enrollment
6
Study type
Interventional
Age
35 Years - 50 Years
Date
Study Start Date: 01 Jun 2011
Primary Completion Date: 01 Sept 2011
Study Completion Date: 01 Sept 2011
Study design
Allocation: N/A
Endpoint Classification: Safety Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verification:
Verified 01 Oct 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: [14C] NKTR-118 | Drug: [14C] NKTR-118 Single 25 mg oral dose administered on Day 1 |
Contacts
Investigators
Principal Investigator
Marianne Kasti
QUINTILES
